1. Home
  2. B²O Introduction
decorative glow

The Exclusive Domestic AI-PBPK Drug R&D Platform

B²O Pharmaceutical’s AI-PBPK platform breaks the boundaries of traditional drug development. Empowered by artificial intelligence for physiologically based pharmacokinetic modeling, it delivers precise prediction across the full lifecycle from early candidate screening to clinical endpoint evaluation. The platform features two exclusive strengths: it is the only dedicated PBPK platform in China, and globally unique in its deep integration of AI algorithms with PBPK modeling, providing irreplaceable value for pharmaceutical R&D clients.

B²O platform full R&D workflow

B²O Pharmaceutical Software R&D Milestones

B²O platform development milestones
decorative glow

Independent Platform Achievements

Software Copyright Certificates Obtained by the Platform

Core Platform Modules

Advantages of AI-PBPK Modeling Platform

AI-PBPK module advantages
Early Stage Assessment

Perform human PK/PD prediction and analysis at early development stages

Molecular Structure Driven

All PBPK parameters predicted by AI, reduced dependence on experimental data

Highly Customizable

Customizable PD models for specific therapeutic indications

Advantages of Drug-Drug Interaction (DDI) Platform

DDI module advantages
Risk Quantitative Assessment

Estimate DDI risk magnitude

Prepare mitigation strategies in advance

Reduce R&D Costs

Leverage strong inducer/inhibitor test data

Eliminate unnecessary experimental expenses

Accelerate R&D Progress

Avoid redundant clinical trials

Identify key drivers of DDI risk

Advantages of Special Formulation Platform

Special formulation module advantages
Special Formulation PK Profiling

Predict drug concentration at target sites

More accurate exposure-response analysis

Risk Factor Control

Integrate in vitro and in vivo data

Support formulation and process optimization

Accelerate R&D Progress

Full lifecycle R&D management

Identify critical formulation development factors

Advantages of Virtual Bioequivalence Platform

Virtual bioequivalence module advantages
Proactive Risk Assessment

Rational evaluation of bioequivalence risk

Reduce unnecessary R&D expenditure

Risk Driver Management

Establish rational IVIVC correlation

Define control criteria for critical variables

Accelerate R&D Progress

Full lifecycle R&D control

Identify root causes of BE failure risks

B²O Pharmaceuticals is an innovative pharmaceutical research and development company dedicated to artificial intelligence (AI)-driven clinical pharmacology and quantitative pharmacology.

Contact information

2022 Copyright © B²O Pharmaceutical Technology (Shanghai) Co., Ltd.

ICP Registration No. Hu ICP 2022000499